Trial reportPsychopharmacology2014
Quetiapine extended-release (Seroquel-XR) versus amitriptyline monotherapy for treating patients with fibromyalgia: a 16-week, randomized, flexible-dose, open-label trial.
Trial report in Psychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 4 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Drug treatments for fibromyalgia: systematic review and network meta-analysis of randomised trials.BMJ medicine · 2026Pooled it
- Effects of pharmacological and non-pharmacological interventions for the management of sleep problems in people with fibromyalgia: a multi-methods evidence synthesis.Health technology assessment (Winchester, England) · 2025Pooled it
- Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment.Nature reviews. Rheumatology · 2020Pooled it
- Antipsychotics for fibromyalgia in adults.The Cochrane database of systematic reviews · 2016Pooled it
- Pharmacological Treatment of Fibromyalgia Syndrome: A Practice-Based Review.Current pain and headache reports · 2024Review
- Management of Fibromyalgia: An Update.Biomedicines · 2024Review
- Fibromyalgia interventions, obstacles and prospects: narrative review.Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology · 2023Review
- Non-invasive brain stimulation for fibromyalgia: current trends and future perspectives.Frontiers in neuroscience · 2023Review
- Review of Fibromyalgia (FM) Syndrome Treatments.International journal of environmental research and public health · 2022Review
- Efficacy and Safety Considerations With Second-Generation Antipsychotics as Adjunctive Analgesics: A Review of Literature.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2021Review
- Does the Rural Environment Influence Symptomatology and Optimize the Effectiveness of Disease Acceptance? A Study Among Women With Fibromyalgia.Frontiers in psychology · 2021Article
- Expert review and recommendations for the management of acute, chronic, and neuropathic pain in Qatar.Qatar medical journal · 2021Article
- Beyond Amitriptyline: A Pediatric and Adolescent Oriented Narrative Review of the Analgesic Properties of Psychotropic Medications for the Treatment of Complex Pain and Headache Disorders.Children (Basel, Switzerland) · 2020Review
- Current and Emerging Pharmacotherapy for Fibromyalgia.Pain research & management · 2020Review
- Psychotropics, Antidepressants, and Visceral Analgesics in Functional Gastrointestinal Disorders.Current gastroenterology reports · 2018Review
- A Brief Review of the Pharmacology of Amitriptyline and Clinical Outcomes in Treating Fibromyalgia.Biomedicines · 2017Review
- Management of fibromyalgia in older adults.Drugs & aging · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationalePrevious open-label studies have suggested that quetiapine could be a valuable alternative for treating fibromyalgia.
objectiveThis study aims to compare the efficacy and tolerability of extended-release quetiapine with amitriptyline for treating fibromyalgia.
methodsThis study was a randomized, open-label, flexible-dose, non-inferiority trial. Patients with fibromyalgia were randomized to receive quetiapine extended-release (XR) (N = 45) (50 to 300 mg daily) or amitriptyline (N = 45) (10 to 75 mg daily) for 16 weeks. The primary endpoint was the change from baseline to endpoint in the Fibromyalgia Impact Questionnaire (FIQ) total score; the non-inferiority threshold was established at 8 points. The secondary outcomes included sleep quality, anxiety, depression, and quality of life.
resultsTwenty-two (49%) patients in the quetiapine group and 34 (76%) patients in the amitriptyline group completed the study. We found a reduction of 9.8 points in the total FIQ score at the endpoint for the quetiapine-treated patients compared to 13.9 points for the amitriptyline-treated patients, for a difference of 4.14 points (80% confidence interval (CI) -0.70 to 8.98). No significant differences were found between the quetiapine XR and amitriptyline groups for any of the secondary outcomes. The proportion of patients discontinuing treatment due to adverse events was higher in the quetiapine group (n = 14, 31.1%) than the amitriptyline group (n = 3, 6.6%).
conclusionsOur results appear to indicate that quetiapine XR does not provide similar efficacy to amitriptyline for treating patients with fibromyalgia. Quetiapine XR had a worse tolerability than amitriptyline in this population, possibly due to a relatively high starting dose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.